Linkedin post 2019

Raising pharmacovigilance awareness in the #MedSafetyWeek

This week is the Annual Pharmacovigilance Week, organized by Uppsala Monitoring Center and led in Spain by Agencia Española de Medicamentos y Productos Sanitarios (AEMPS).

For one week in November, medicine regulators across the globe simultaneously share campaign materials on their social media channels, with the hashtag #MedSafetyWeek. The campaign of this year focuses on polypharmacy (which is defined as five or more medications) and the safe use of medicines in the elderly or those with complex conditions.

It has been published that currently one third of the world’s population over 75 years old take at least six medications per day, and more than one million people consume eight or more.

As a Contract Research Organization part of our work include monitoring clinical studies in which patient have a special conditions (most of them suffer chronic diseases and usually are elderly patients), therefore we need to be aware of this condition can increase the likelihood of suffer adverse drug reactions.

For more detailed information: La AEMPS celebra la #MedSafetyWeek con una campaña para sensibilizar sobre la importancia de notificar las sospechas de reacciones adversas a medicamentosmedsafetyweek

Scientific Reports

Acknowledgment for APICES collaboration in a clinical trial published in Scientific Reports.

This month, we want to share the acknowledgment that APICES has received in a recent publication in Scientific Reports in which APICES has collaborated in several tasks of the project. This means to all APICES team an extra motivation in order to give continuity to the implication we have in every project in which we collaborate. From APICES, we are pride because of the recognition of our work and we want to thank Dr. María Luisa Lozano and Dr. Vicente Vicente for the opportunity they have given to APICES to appear in the publication acknowledgments, and congratulate them and the rest of collaborating invetigators for their project success.

This retrospective multicenter study with long-term follow-up offers insight into some of the most relevant real-world challenges in the treatment of ITP patients with thrombopoietin-receptor agonist (TPO-RA). Data reflect that in clinical practice, the patient’s hemorrhagic risk determines the choice TPO-RA, and distinguishes novel variables associated with vascular events under therapies with thrombopoietic agents.

For more detailed information: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia